Comparative Pharmacology
Head-to-head clinical analysis: AMARYL versus DIABETA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMARYL versus DIABETA.
AMARYL vs DIABETA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, causing channel closure and calcium influx.
Glyburide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to cell depolarization and calcium influx.
Initial dose 1-2 mg orally once daily, titrated to target glucose. Maximum dose 8 mg daily.
Initial: 2.5-5 mg orally once daily, titrating to max 20 mg/day in 1-2 divided doses. Maintenance: 5-10 mg/day.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours; clinically, dosing is once daily due to sustained glucose-lowering effect beyond half-life.
Terminal elimination half-life is approximately 10–12 hours in healthy individuals. Clinically, this supports once-daily dosing; may be prolonged in renal impairment.
Approximately 60% excreted renally as metabolites (mainly M1 and M2) and 40% in feces; <1% excreted unchanged.
Approximately 50% renal (unchanged drug and metabolites), 50% biliary/fecal. Renal elimination accounts for 50% of dose, with about 20% unchanged and 30% as metabolites. Biliary excretion of metabolites contributes to fecal elimination.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic